During the last three months, 13 analysts shared their evaluations of Avidity Biosciences (NASDAQ:RNA), revealing diverse outlooks from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of $72.00, and a low estimate of $48.00. Marking an increase of 1.67%, the current average surpasses the previous average price target of $65.22.

Decoding Analyst Ratings: A Detailed Look

The analysis of recent analyst actions sheds light on the...